Showing results (1-10 of 35) with videos related to
Sort By:
Pageof 4
The Prostate|August 12, 2014
Subgroups of familial and aggressive prostate cancer with considerable frequencies of BRCA2 mutationsChristiane Maier, Kathleen Herkommer, Manuel Luedeke, et al.European Urology|July 30, 2016
Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate CancerChristof Bernemann, Thomas J Schnoeller, Manuel Luedeke, et al.Mutagenesis|December 18, 2010
Heritability of baseline and induced micronucleus frequenciesHarald Surowy, Antje Rinckleb, Manuel Luedeke, et al.DNA Repair|June 9, 2012
The prostate cancer risk locus at 10q11 is associated with DNA repair capacityAntje E Rinckleb, Harald M Surowy, Manuel Luedeke, et al.The Prostate|December 18, 2009
POU5F1P1, a putative cancer susceptibility gene, is overexpressed in prostatic carcinomaSilvia Kastler, Lisa Honold, Manuel Luedeke, et al.Clinical Epigenetics|October 20, 2017
Mosaic genome-wide maternal isodiploidy: an extreme form of imprinting disorder presenting as prenatal diagnostic challengeSusanne Bens, Manuel Luedeke, Tanja Richter, et al.American Journal of Epidemiology|April 9, 2015
Obesity and Prostate Cancer Risk According to Tumor TMPRSS2:ERG Gene Fusion StatusLieke Egbers, Manuel Luedeke, Antje Rinckleb, et al.Cancer Genetics and Cytogenetics|April 15, 2008
Expression changes of CAV1 and EZH2, located on 7q31 approximately q36, are rarely related to genomic alterations in primary prostate carcinomaNatascha Bachmann, Juergen Haeusler, Manuel Luedeke, et al.Plos One|June 3, 2014
Stilbene induced inhibition of androgen receptor dimerization: implications for AR and ARΔLBD-signalling in human prostate cancer cellsWolfgang Streicher, Manuel Luedeke, Anca Azoitei, et al.Plos One|March 30, 2012
Prostate cancer risk is not altered by TP53AIP1 germline mutations in a German case-control seriesManuel Luedeke, Irina Coinac, Carmen M Linnert, et al.Pageof 4